Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 10 of 10 for “"Universal CAR"”.

  1. Determining the histocompatibility barriers between Universal CAR T (UCART) cells and NK cells

    … the histocompatibility barriers between universal CAR T cells (UCART) and NK cellsKimberly Apodaca Gerald P. Linette Allogeneic chimeric antigen receptor (CAR) T cell therapies hold promise for certain malignant disorders as they allow for scalability, on-demand availability, and enhanced …

    penn Repository record for Determining the histocompatibility barriers between Universal CAR T (UCART) cells and NK cells (opens in a new tab)

  2. Enhancing CAR T cell safety with new universal CAR systems and anatomically restricted tumor targeting

    Chimeric antigen receptor (CAR) T cells are a potent class of immunotherapy that have revolutionized the treatment of hematological malignancies. However, high relapse rates and severe side effects have limited their impact. As the field progresses and CAR T cells are used to target more complex …

    washington Repository record for Enhancing CAR T cell safety with new universal CAR systems and anatomically restricted tumor targeting (opens in a new tab)

  3. Clinical-scale development of universal CAR regulatory T cells guided by insights from polyclonal therapy

    … therapies, such as Chimeric Antigen Receptor (CAR)-Treg therapies and led to the establishment of a clinical-scale, GMP-compatible manufacturing process. To further advance the therapy, a universal CAR product was developed to broaden clinical applicability and reduce future development time …

    qucosa-diss

  4. Engineering universal chimeric antigen receptor systems to expand cell therapy applications

    Adoptive chimeric antigen receptor (CAR) T cell therapy has proved a remarkable breakthrough in cancer treatment, with six FDA-approved therapies to date. This progress has motivated research efforts to expand its application to more complex cancer targets, as well as other diseases marked by …

    bu Repository record for Engineering universal chimeric antigen receptor systems to expand cell therapy applications (opens in a new tab)

  5. Aptamers and Peptides: Finding and Guiding CAR T Cells for Better Cancer Care

    Chimeric antigen receptor (CAR) T-cell therapy has prompted a new age of cancer treatments, in which a patient’s T cells are genetically programmed with a cancer-targeting receptor ex vivo and reinfused for immune-mediated clearance of the tumor. However, despite some success in treating CD19+ …

    washington Repository record for Aptamers and Peptides: Finding and Guiding CAR T Cells for Better Cancer Care (opens in a new tab)

  6. Developing an engineered T cell product for universal vaccination-based boosting in adoptive cell therapies

    Creating a universal-prime boost strategy using multi-specific T cells from the tumour infiltrating lymphocytes (TIL) population can enhance the success of adoptive T cell therapies (ACT). ACT, as a personalized living-drug, is often a last resort due to its extensive time, cost, and labor …

    mcmaster Repository record for Developing an engineered T cell product for universal vaccination-based boosting in adoptive cell therapies (opens in a new tab)

  7. Synthetic receptor engineering for immune control: precision targeting of autoreactive T cells and quantitative dissection of T cell fate

    … into conventional chimeric antigen receptors (CARs), universal CAR platforms, and mRNA-delivered bispecific T cell engagers. Through these studies, I established modular approaches for antigen-directed immune modulation and evaluated their functionality using in vitro T cell systems. In the …

    bu Repository record for Synthetic receptor engineering for immune control: precision targeting of autoreactive T cells and quantitative dissection of T cell fate (opens in a new tab)

  8. Engineering biomaterial-enhanced therapeutics to control locally aggressive malignancies

    … them ideal delivery vehicles for intraoperative care in the context of local tumor resection. We optimized the meshes to deliver the chemotherapeutic doxorubicin via drug encapsulation within the nanofibers and within hydrophobic coatings made of poly(glycerol mono-stearate-co-caprolactone) …

    bu Repository record for Engineering biomaterial-enhanced therapeutics to control locally aggressive malignancies (opens in a new tab)

  9. Development and preclinical evaluation of tumour-reactive T cells expressing a chemically programmable chimeric antigen receptor

    … for the expression a chimeric antigen receptor (CAR) endows them with a new specificity for an antigen. Adoptive immunotherapy with CD19-CAR T cells has achieved high rates of sustained complete remissions in B cell malignancies. However, the downregulation or loss of the targeted antigen after …

    wurz-thes Repository record for Development and preclinical evaluation of tumour-reactive T cells expressing a chemically programmable chimeric antigen receptor (opens in a new tab)

  10. Adaptation of a switchable CAR technology for the treatment of glioblastoma

    … treatment options. The current standard of care, involving surgery, radiotherapy, and chemotherapy, often fails to prevent recurrence due to the tumor's invasive nature and immunosuppressive microenvironment. Immunotherapy has emerged as a promising avenue for GBM treatment, aiming to …

    qucosa-diss